[Leflunomide for therapy of rheumatoid arthritis].
Nakajima
Ayako
A
Institute of Rheumatology, Tokyo Women's Medical University.
Yamanaka
Hisashi
H
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000077339:Leflunomide; D017563:Lung Diseases, Interstitial / Q000139:chemically induced; D020782:Matrix Metalloproteinases / Q000378:metabolism; D010088:Oxidoreductases / Q000037:antagonists & inhibitors; D013601:T-Lymphocytes / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007555:Isoxazoles; D014409:Tumor Necrosis Factor-alpha; D010088:Oxidoreductases; C019999:dehydroorotate dehydrogenase; D020782:Matrix Metalloproteinases; D000077339:Leflunomide